कृपया अन्य खोज का प्रयास करें
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Jonathan Kenneth Charles Knowles | 75 | 2015 | Chairman of the Scientific Advisory Board |
John Poulos | 70 | 2017 | Independent Non-Executive Director |
Huaizheng Peng | 62 | 2015 | Board Observer |
Christophe Massard | - | 2019 | Member of the Scientific Advisory Board |
David Adams | - | 2019 | Member of the Scientific Advisory Board |
Marie-Louise Helena Fjallskog | 60 | 2022 | Independent Non-Executive Director |
Christine Ann Roth | 61 | 2023 | Independent Non-Executive Director |
Sirpa Jalkanen | 70 | 2019 | Member of the Scientific Advisory Board |
Tyler Curiel | - | 2021 | Member of the Scientific Advisory Board |
Tuomo Patsi | 60 | 2023 | Independent Non-Executive Chairman |
Markku Tapani Jalkanen | 70 | 2006 | Founder & Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है